Kck Ltd. Takes Position in NeuroPace, Inc. (NASDAQ:NPCE)

Kck Ltd. bought a new position in shares of NeuroPace, Inc. (NASDAQ:NPCE) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 5,270,845 shares of the company’s stock, valued at approximately $58,981,000. NeuroPace accounts for about 78.7% of Kck Ltd.’s portfolio, making the stock its largest holding. Kck Ltd. owned 0.18% of NeuroPace as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its position in NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after purchasing an additional 6,181 shares during the last quarter. Barclays PLC boosted its holdings in shares of NeuroPace by 346.0% in the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after buying an additional 16,007 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of NeuroPace by 8.7% in the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after buying an additional 25,330 shares in the last quarter. State Street Corp grew its stake in shares of NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after buying an additional 12,912 shares in the last quarter. Finally, Financial Advocates Investment Management increased its holdings in NeuroPace by 20.0% during the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after buying an additional 3,000 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

Insider Activity at NeuroPace

In related news, major shareholder Ltd. Kck sold 223,991 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $5.45, for a total transaction of $1,220,750.95. Following the transaction, the insider now directly owns 5,270,845 shares of the company’s stock, valued at approximately $28,726,105.25. This trade represents a 4.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 227,858 shares of company stock worth $1,244,328 in the last ninety days. 22.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on NPCE shares. Wells Fargo & Company cut their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, NeuroPace currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

NeuroPace Stock Up 0.5 %

Shares of NPCE opened at $11.97 on Friday. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The company’s 50-day moving average is $10.82 and its 200-day moving average is $8.40. NeuroPace, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $18.15.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The firm had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. During the same period last year, the business posted ($0.28) earnings per share. As a group, equities research analysts anticipate that NeuroPace, Inc. will post -1 EPS for the current year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.